Abstract: SA-PO650
Effect of Roxadustat vs. Erythropoietin on Nutritional Status in Peritoneal Dialysis Patients: A Retrospective Study
Session Information
- Home Dialysis - II
November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 802 Dialysis: Home Dialysis and Peritoneal Dialysis
Authors
- Luo, Xiao Jie, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China
- Luo, Qimei, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China
- Dou, Xianrui, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China
Background
Roxadustat have been used to treat renal anemia in patients undergoing dialysis. The effect of roxadustat on nutritional status in peritoneal dialysis (PD) patients remains uncertain. We aimed to explore the effect of roxadustat on nutritional status, and explore the possible modifiers for the association in PD patients.
Methods
The current study included 136 PD patients with renal anemia. The primary efficacy endpoints included changes from baseline in nutrition-related parameters. Linear regression analysis was performed to analyze the correlation between use of roxadustat with Subjective Global Assessment (SGA) and Malnutrition-Inflammation Score (MIS). Logistics regression analysis was used to evaluate the risk factors for the indicators of MIS.
Results
After a median treatment observation of 20.0 (25th-75th, 16.0–21.0) months, the changes from baseline in serum albumin, prealbumin, total cholesterol, high-density lipoprotein cholesterol, blood urea nitrogen and creatinine levels were not significantly different between two groups. Besides, the use of roxadustat was inversely associated with MIS (β, -0.263; 95% CI: -2.430, -0.096), and was positively associated with SGA (β, 0.440; 95% CI: 0.046, 0.834). Additionally, compared to patients in rHuEPO group, those with the use of roxadustat were associated with more dietary intake (OR, 0.405; 95% CI: 0.190-0.865) and fewer gastrointestinal symptoms (OR, 0.365; 95% CI: 0.164-0.809). The inverse association between the use of roxadustat with MIS was stronger in patients without RRF (P for interaction=0.019).
Conclusion
In short, this study found that the use of roxadustat was inversely associated with MIS and positively associated with SGA in PD patients.